Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Perspective Therapeutics, Inc.ISR · Entity 694 | Chief R&D Officer | July 21, 2022 | August 01, 2022 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Perspective Therapeutics, Inc.
Report date July 21, 2022 · Filed August 01, 2022
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Options (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.33 · Expires 2032-07-21 | Direct | 1,493,846 |
Reported balance
After 2022-07-21 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2022-07-21 · Grant · Acquired 475,000 · Balance 1,493,846 F1: 25% vested as of 7/21/2022, and the remaining 75% will vest over the next three (3) years, commencing on 7/21/2023, until fully vested. |
Filing footnotes · ownership attribution and instrument terms
F1: 25% vested as of 7/21/2022, and the remaining 75% will vest over the next three (3) years, commencing on 7/21/2023, until fully vested.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| July 21, 2022 Filed Aug 1, 2022 23:18 UTC | Perspective Therapeutics, Inc. ISR · Entity 694 | GrantStock Options (right to buy) · Derivative | 475,000 | $0.00 Strike: $0.33 | $0.00 |
DisclosureSEC source: 0001437749-22-018298 · rdgdoc.xml · derivative · entry 1 Cavanagh William · CIK 0001503593 · Chief R&D Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,493,846 Underlying: Common Stock · 475,000 shares Expires 2032-07-21 F1 · derivative.exercise_date: 25% vested as of 7/21/2022, and the remaining 75% will vest over the next three (3) years, commencing on 7/21/2023, until fully vested. Read SEC document |
| July 01, 2021 Filed Jul 6, 2021 20:33 UTC | Perspective Therapeutics, Inc. ISR · Entity 694 | GrantStock Options (right to buy) · Derivative | 320,000 | $0.00 Strike: $0.79 | $0.00 |
DisclosureSEC source: 0001437749-21-016459 · rdgdoc.xml · derivative · entry 1 Cavanagh William · CIK 0001503593 · Chief R&D Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,025,506 Underlying: Common Stock · 320,000 shares Expires 2031-07-01 F1 · derivative.exercise_date: 25% vested as of 7/1/2021, and the remaining 75% will vest over the next three (3) years, commencing on 7/1/2022, until fully vested. Read SEC document |
| October 22, 2020 Filed Oct 28, 2020 20:41 UTC | Perspective Therapeutics, Inc. ISR · Entity 694 | PurchaseWarrant (right to buy) · Derivative | 3,846 | $0.00 Strike: $0.57 | $0.00 |
DisclosureSEC source: 0001437749-20-021855 · rdgdoc.xml · derivative · entry 2 Cavanagh William · CIK 0001503593 · Chief R&D Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 705,506 Underlying: Common Stock · 3,846 shares Expires 2025-10-22 F2 · shares: Purchased pursuant to public offering that closed on October 22, 2020. Each share of common stock purchased included one-half of a warrant. Each whole warrant is exercisable to purchase one share of common stock at an exercise price of $0.57 per share. Each warrant is immediately exercisable, and will expire October 22, 2025. F2 · derivative.exercise_date: Purchased pursuant to public offering that closed on October 22, 2020. Each share of common stock purchased included one-half of a warrant. Each whole warrant is exercisable to purchase one share of common stock at an exercise price of $0.57 per share. Each warrant is immediately exercisable, and will expire October 22, 2025. F2 · derivative.expiration_date: Purchased pursuant to public offering that closed on October 22, 2020. Each share of common stock purchased included one-half of a warrant. Each whole warrant is exercisable to purchase one share of common stock at an exercise price of $0.57 per share. Each warrant is immediately exercisable, and will expire October 22, 2025. Read SEC document |
| October 22, 2020 Filed Oct 28, 2020 20:41 UTC | Perspective Therapeutics, Inc. ISR · Entity 694 | PurchaseCommon Stock | 7,692 | $0.52 | $3,999.84 |
DisclosureSEC source: 0001437749-20-021855 · rdgdoc.xml · nonDerivative · entry 1 Cavanagh William · CIK 0001503593 · Chief R&D Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,692 F1 · shares: Purchased pursuant to public offering that closed on October 22, 2020. F1 · price: Purchased pursuant to public offering that closed on October 22, 2020. Read SEC document |
| June 23, 2020 Filed Jun 25, 2020 20:42 UTC | Perspective Therapeutics, Inc. ISR · Entity 694 | GrantStock Options (right to buy) · Derivative | 150,000 | $0.00 Strike: $0.61 | $0.00 |
DisclosureSEC source: 0001437749-20-013874 · rdgdoc.xml · derivative · entry 1 Cavanagh William · CIK 0001503593 · Chief R&D Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 701,660 Underlying: Common Stock · 150,000 shares Expires 2030-06-23 F1 · derivative.exercise_date: 25% vested as of 6/23/2020, and the remaining 75% will vest over the next three (3) years, commencing on 6/23/2021, until fully vested. Read SEC document |
| November 15, 2019 Filed Nov 19, 2019 22:01 UTC | Perspective Therapeutics, Inc. ISR · Entity 694 | PurchaseCommon Stock | 10,000 | $0.39 | $3,900.00 |
DisclosureSEC source: 0001437749-19-023220 · rdgdoc.xml · nonDerivative · entry 1 Cavanagh William · CIK 0001503593 · Chief R&D Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 Read SEC document |
| June 18, 2019 Filed Jun 27, 2019 20:16 UTC | Perspective Therapeutics, Inc. ISR · Entity 694 | GrantStock Options (right to buy) · Derivative | 150,000 | $0.00 Strike: $0.43 | $0.00 |
DisclosureSEC source: 0001437749-19-012916 · rdgdoc.xml · derivative · entry 1 Cavanagh William · CIK 0001503593 · Chief R&D Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 551,660 Underlying: Common Stock · 150,000 shares Expires 2029-06-18 F1 · derivative.exercise_date: 25% vested as of 6/18/2019, and the remaining 75% will vest over the next three (3) years, commencing on 6/18/2020, until fully vested. Read SEC document |
| November 16, 2018 Filed Nov 16, 2018 23:37 UTC | Perspective Therapeutics, Inc. ISR · Entity 694 | PurchaseCommon Stock | 10,000 | $0.40 | $4,000.00 |
DisclosureSEC source: 0001437749-18-021027 · rdgdoc.xml · nonDerivative · entry 1 Cavanagh William · CIK 0001503593 · COO, CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,000 Read SEC document |
| June 13, 2018 Filed Jun 20, 2018 00:23 UTC | Perspective Therapeutics, Inc. ISR · Entity 694 | GrantStock Options (right to buy) · Derivative | 150,000 | $0.00 Strike: $0.46 | $0.00 |
DisclosureSEC source: 0001437749-18-012091 · rdgdoc.xml · derivative · entry 1 Cavanagh William · CIK 0001503593 · COO, CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 401,660 Underlying: Common Stock · 150,000 shares Expires 2028-06-13 F1 · derivative.exercise_date: 25% vested as of 6/13/2018, and the remaining 75% will vest over the next three (3) years, commencing on 6/13/2019, until fully vested. Read SEC document |
| June 27, 2017 Filed Jun 29, 2017 21:19 UTC | Perspective Therapeutics, Inc. ISR · Entity 694 | GrantStock Options (right to buy) · Derivative | 225,000 | $0.00 Strike: $0.61 | $0.00 |
DisclosureSEC source: 0001642247-17-000011 · primary_doc.xml · derivative · entry 3 Cavanagh William · CIK 0001503593 · COO, CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 225,000 shares Expires 2027-06-27 F1 · security: The three reported transactions involved a termination of outstanding options, resulting in the deemed cancellation of the old options and the grant of a new option. F2 · derivative.exercise_date: 25% vested as of 6/27/2017, and the remaining 75% will vest over the next three (3) years, commencing on 6/27/2018, until fully vested. Read SEC document |
| June 15, 2017 Filed Jun 29, 2017 21:19 UTC | Perspective Therapeutics, Inc. ISR · Entity 694 | Disposition to issuerStock Options (right to buy) · Derivative | 125,000 | $0.00 Strike: $0.93 | $0.00 |
DisclosureSEC source: 0001642247-17-000011 · primary_doc.xml · derivative · entry 2 Cavanagh William · CIK 0001503593 · COO, CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 125,000 shares Expires 2026-06-21 F1 · security: The three reported transactions involved a termination of outstanding options, resulting in the deemed cancellation of the old options and the grant of a new option. F1 · derivative.exercise_date: The three reported transactions involved a termination of outstanding options, resulting in the deemed cancellation of the old options and the grant of a new option. Read SEC document |
| June 15, 2017 Filed Jun 29, 2017 21:19 UTC | Perspective Therapeutics, Inc. ISR · Entity 694 | Disposition to issuerStock Options (right to buy) · Derivative | 20,000 | $0.00 Strike: $1.47 | $0.00 |
DisclosureSEC source: 0001642247-17-000011 · primary_doc.xml · derivative · entry 1 Cavanagh William · CIK 0001503593 · COO, CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 20,000 shares Expires 2025-06-18 F1 · security: The three reported transactions involved a termination of outstanding options, resulting in the deemed cancellation of the old options and the grant of a new option. F1 · derivative.exercise_date: The three reported transactions involved a termination of outstanding options, resulting in the deemed cancellation of the old options and the grant of a new option. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.